StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
"Regeneration-inducing Medicine".
July 01, 2024 | IR News | Noteice of Extraordinary General Meeting of Shareholders |
---|---|---|
June 12, 2024 | Financial Results | Non-consolidated Financial Results for the Nine Months Ended April 30, 2024 [Japanese GAAP] |
March 21, 2024 | IR News | StemRIM Announces Symposium on “Regeneration-Inducing Medicine” at the 23rd Congress of the Japanese Society for Regenerative Medicine |
March 15, 2024 | Financial Results Presentation Materials | Presentation Materials for Six Months Ended January 31, 2024 |
March 13, 2024 | Financial Results | Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP] |
April 25, 2023 | NEWS Release |
---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, "Regeneration-inducing Medicine".
"Regeneration-inducing Medicine" is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.